Indications -- Hepatitis Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- Hepatitis

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (73)	6/29/2004 11:59:09 AM
From: zeta1961	Read Replies (1) of 312

Thanks for posting that Rick...been a heated debate... Parking some DDW 2204 data...and a few historicals for Schering/Pegasys Commentary welcome...going to post a summary in answer to Peter's question last week on the valuation thread... hivandhepatitis.com Pegasys with more stable concentration levels than PegIntron...sponsored by Roche...scientific detail about HCV viral kinetics and pharmakodynamics comparison...imo, interesting, edifying...uses benchmark studies currently referenced by other researchers/ manufacturers hivandhepatitis.com comparison of QOL PegIntron vs. Pegasys hivandhepatitis.com Another QOL study for Pegasys hivandhepatitis.com co-occurring substance use and HCV hivandhepatitis.com An activists testimony re: Schering in 2001 hivandhepatitis.com Schering and Roche settle patent disputes hivandhepatitis.com Pegasys gains 50% market share of Schering's PegIntron hivandhepatitis.com a case for twice weekly PegIntron vs. weekly hivandhepatitis.com 21% response rate for G1 non responders re-treated with Peg Intron A+ Ribavirin 800mg/day who failed conventional IFN hivandhepatitis.com Pegasys and G1 non-responders...41% average viral response at 24 week treatment timeline...svr pending hivandhepatitis.com suicidal ideation with IFN based tx... hivandhepatitis.com Infergen in non-responders...no washout period...Ribavirin dose 1000-1200, 43% end of treatment virologic response...awating 24 week post treatment SVR hivandhepatitis.com epo and weight based Ribavirin... hivandhepatitis.com Pegasys+amantadine or ribavirin...ribavirin with better results hivandhepatitis.com Predicting SVR as early as one week and 4 weeks hivandhepatitis.com a case for weight based ribavirin therapy hivandhepatitis.com Schering's SCH 6 oral inhibitor preclinicals no human data yet hivandhepatitis.com VX 497+Pegasys+ ribavirin in non responders...dose escalating study...6/7 patients on 50mg dose with 86% response hivandhepatitis.com Idenix NM 283...Well tolerated...negative HCV at 14 day treatment but relapse after drug discontinuation...to be evaluated for long term use and with interferon combination hivandhepatitis.com Viramidine vs. Ribavirin and anemia, viral control hivandhepatitis.com Long term Epo...less Ribavirin dose reduction while maintaining adequate HgB levels hivandhepatitis.com Factors that improve efficacy of Epo...monitoring, nursing practice, insurance coverage hivandhepatitis.com Darbepoetin(Aranesp) q2weeks and anemia control in ribavirin based tx. hivandhepatitis.com Infergen + actimmune initiated in patients who failed to respond with at least 2logx10 drop @12 weeks results at 12 weeks I and A:...38% HCV negative, 65% greater than 2logX10 drop or HCV negative...study ongoing hivandhepatitis.com High dose Infergen and combo in Peg Intron non responders...low dose infergin alone /high dose infergin alone induction, then low dose/high dose+ribavirin maintenance end of tx response: 42%/48%...SVR 24% hivandhepatitis.com Urban clinic SVR's compared to clinical trial setting hivandhepatitis.com How long to treat non-responders? Peg-Intron study hivandhepatitis.com Schering "most HCV infected patients not eligible for interferon...not sure what to make of the #'s as they suggest the majority do accept treatment...commentary welcome hivandhepatitis.com "Ideal trial" design analysis and commentary Pegasys vs. PegIntron in treatment naive genotype 1 patients... all above links from highlights of DDW 2004 hivandhepatitis.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next